My experience surviving a life-threatening infection led to my role as the CF community co-chair of the Cystic Fibrosis Foundation's Infection Research Initiative. Having a room full of leading scientists listen to my story helped renew my faith that we can tackle the complex challenge of difficult-to-treat infections.
Site Search
The Cystic Fibrosis Foundation awarded up to $5 million to Armata Pharmaceuticals for the first-ever controlled clinical study of phage therapy in CF, reaffirming the Foundation's commitment to advance innovative solutions to the growing challenge of antibiotic resistance.
The Cystic Fibrosis Foundation has awarded up to $5.6 million to Microbion Corporation to develop a novel, inhaled antibiotic to treat drug-resistant bacterial infections in people with cystic fibrosis.
Thirty-three new projects are being funded as part of the Foundation's $100 million Infection Research Initiative.
Although 90-95 percent of people with cystic fibrosis are expected to benefit from CF transmembrane regulator (CFTR) modulators, 5 percent of the population will still need alternative therapies to address the underlying cause of their disease. Learn more about the research that the Cystic Fibrosis Foundation is doing to find treatments for the 5 percent of people with these rare and nonsense mutations.
This year, theratyping, the process of matching medications with mutations, enabled more people with cystic fibrosis who have rare mutations to benefit from modulators. In the first plenary at the NACFC, we heard more about how theratyping will be used, as well as other future advances coming in CF treatment.
The Cystic Fibrosis Foundation has entered into an agreement with Synspira Therapeutics Inc. to develop a non-porcine enzyme replacement therapy to offer an alternative to people with cystic fibrosis who cannot digest food properly.
As both a researcher and a person with cystic fibrosis, it is an amazing experience to watch cells with rare CF mutations respond to drugs in the lab. Knowing the scientific basis for my treatments not only gives me a sense of control, but it encourages me to do my treatments.
On July 9, the Cystic Fibrosis Foundation's President and CEO, Dr. Michael P. Boyle, participated in the global launch of the AMR Action Fund. Alongside leaders in global health, Dr. Boyle highlighted the critical need of antibiotics for people living with CF and stressed that research investment alone will not solve the challenges of antibiotic development.
Clarametyx’s novel therapy aims to disrupt bacterial biofilms, one of the primary causes of antibiotic resistance, thereby potentially increasing the effectiveness of existing treatments in fighting a wide range of bacterial infections, including those commonly affecting people with CF.